Home Healthcare Biotechnology Cell-free DNA Testing Market

Cell-free DNA Testing Market Size, Share & Trends Analysis Report By Type (Cell-free Fetal DNA, Circulating Tumor DNA, Donor-derived cfDNA), By Technology (Massive Parallel Shotgun Sequencing, Targeted MP Sequencing, Single-Nucleotide Polymorphism, Digital PCR), By Application (Gynecology/Prenatal Testing, Oncology, Transplantation, Others), By End User (Clinical Laboratories, Hospitals, Research & Academic Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 20, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cell-free DNA Testing Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Cell-free Fetal DNA
    2. Circulating Tumor DNA
    3. Donor-derived cfDNA
  2. Cell-free DNA Testing Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Massive Parallel Shotgun Sequencing
    2. Targeted MP Sequencing
    3. Single-Nucleotide Polymorphism
    4. Digital PCR
  3. Cell-free DNA Testing Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Gynecology/Prenatal Testing
    2. Oncology
    3. Transplantation
    4. Others
  4. Cell-free DNA Testing Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Clinical Laboratories
    2. Hospitals
    3. Research & Academic Institutes
  5. Regional Cell-free DNA Testing Market
    1. North America
      1. North America Cell-free DNA Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
      2. North America Cell-free DNA Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Massive Parallel Shotgun Sequencing
        2. Targeted MP Sequencing
        3. Single-Nucleotide Polymorphism
        4. Digital PCR
      3. North America Cell-free DNA Testing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gynecology/Prenatal Testing
        2. Oncology
        3. Transplantation
        4. Others
      4. North America Cell-free DNA Testing Market By End User 2022-2034 (USD MILLION/ Units)
        1. Clinical Laboratories
        2. Hospitals
        3. Research & Academic Institutes
      5. U.S.
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      6. Canada
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
    2. Europe
      1. Europe Cell-free DNA Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
      2. Europe Cell-free DNA Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Massive Parallel Shotgun Sequencing
        2. Targeted MP Sequencing
        3. Single-Nucleotide Polymorphism
        4. Digital PCR
      3. Europe Cell-free DNA Testing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gynecology/Prenatal Testing
        2. Oncology
        3. Transplantation
        4. Others
      4. Europe Cell-free DNA Testing Market By End User 2022-2034 (USD MILLION/ Units)
        1. Clinical Laboratories
        2. Hospitals
        3. Research & Academic Institutes
      5. U.K.
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      6. Germany
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      7. France
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      8. Spain
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      9. Italy
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      10. Russia
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      11. Nordic
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      12. Benelux
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      13. Rest of Europe
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
    3. APAC
      1. APAC Cell-free DNA Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
      2. APAC Cell-free DNA Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Massive Parallel Shotgun Sequencing
        2. Targeted MP Sequencing
        3. Single-Nucleotide Polymorphism
        4. Digital PCR
      3. APAC Cell-free DNA Testing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gynecology/Prenatal Testing
        2. Oncology
        3. Transplantation
        4. Others
      4. APAC Cell-free DNA Testing Market By End User 2022-2034 (USD MILLION/ Units)
        1. Clinical Laboratories
        2. Hospitals
        3. Research & Academic Institutes
      5. China
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      6. Korea
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      7. Japan
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      8. India
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      9. Australia
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      10. Taiwan
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      11. South East Asia
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      12. Rest of Asia-Pacific
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
    4. Middle East and Africa
      1. Middle East and Africa Cell-free DNA Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
      2. Middle East and Africa Cell-free DNA Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Massive Parallel Shotgun Sequencing
        2. Targeted MP Sequencing
        3. Single-Nucleotide Polymorphism
        4. Digital PCR
      3. Middle East and Africa Cell-free DNA Testing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gynecology/Prenatal Testing
        2. Oncology
        3. Transplantation
        4. Others
      4. Middle East and Africa Cell-free DNA Testing Market By End User 2022-2034 (USD MILLION/ Units)
        1. Clinical Laboratories
        2. Hospitals
        3. Research & Academic Institutes
      5. UAE
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      6. Turkey
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      7. Saudi Arabia
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      8. South Africa
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      9. Egypt
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      10. Nigeria
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      11. Rest of MEA
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
    5. LATAM
      1. LATAM Cell-free DNA Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
      2. LATAM Cell-free DNA Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Massive Parallel Shotgun Sequencing
        2. Targeted MP Sequencing
        3. Single-Nucleotide Polymorphism
        4. Digital PCR
      3. LATAM Cell-free DNA Testing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gynecology/Prenatal Testing
        2. Oncology
        3. Transplantation
        4. Others
      4. LATAM Cell-free DNA Testing Market By End User 2022-2034 (USD MILLION/ Units)
        1. Clinical Laboratories
        2. Hospitals
        3. Research & Academic Institutes
      5. Brazil
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      6. Mexico
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      7. Argentina
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      8. Chile
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      9. Colombia
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
      10. Rest of LATAM
        1. Cell-free Fetal DNA
        2. Circulating Tumor DNA
        3. Donor-derived cfDNA
        4. Massive Parallel Shotgun Sequencing
        5. Targeted MP Sequencing
        6. Single-Nucleotide Polymorphism
        7. Digital PCR
        8. Gynecology/Prenatal Testing
        9. Oncology
        10. Transplantation
        11. Others
        12. Clinical Laboratories
        13. Hospitals
        14. Research & Academic Institutes
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.